The group's principal activities are to develop, manufacture, promote and market pharmaceuticals and other biotech products. The group focuses on the development of pharmaceuticals based on human protein elafin which naturally occurs in human skin, lungs, and mammary glands. This human protein is useful in the treatment of cardiac infarction, serious injuries caused by accidents, post surgery damage to tissue and complications resulting from organ transplantations. The group is a development stage company.
